{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:58:19Z","timestamp":1790794699426,"version":"4.1.0"},"reference-count":32,"publisher":"Begell House","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Immunol"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>Natural killer (NK) cells play a key role in targeting cancer, virus-infected, and senescent cells through direct cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC). Monitoring NK cell cytotoxicity is crucial for evaluating immune function, tracking disease progression, and assessing therapeutic outcomes, particularly in oncology and immunology. NK cells help manage infections, cancer, and other health conditions through their cytotoxic actions. Changes in NK activity can signal disease states or responses to treatments. NK cell-based therapies require functional assessments to maximize effectiveness. Abnormal NK cytotoxicity may be linked to autoimmune diseases or immune exhaustion in tumor microenvironments. Various methods are used to measure NK cell cytotoxicity, with the chromium-51 release assay once being the gold standard by detecting radioactive chromium release upon target cell destruction. This report highlights the significant potential of a label-free impedance-based Real Time Cell Analysis (RTCA) platform with complementary live cell imaging capability for label-free, dynamic monitoring of NK-target cell interactions over time.<\/p>","DOI":"10.1615\/critrevimmunol.2025061706","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:06:06Z","timestamp":1762445166000},"page":"1-6","source":"Crossref","is-referenced-by-count":0,"title":["Label-Free Impedance-Based Real-Time Cell Analysis Platform: An Advanced Technology Designed to Monitor the Cytotoxic Activity of Natural Killer Cells"],"prefix":"10.1615","volume":"46","author":[{"given":"Kawaljit","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ. 2008;15(2):226-33.","DOI":"10.1038\/sj.cdd.4402170"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-74.","DOI":"10.1146\/annurev.immunol.23.021704.115526"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Magister S, Tseng HC, Bui VT, Kos J, Jewett A. Regulation of split anergy in natural killer cells by inhibition of cathepsins C and H and cystatin F. Oncotarget. 2015;6(26):22310-27.","DOI":"10.18632\/oncotarget.4208"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Kale A, Sharma A, Stolzing A, Desprez PY, Campisi J. Role of immune cells in the removal of deleterious senescent cells. Immun Ageing. 2020;17:16.","DOI":"10.1186\/s12979-020-00187-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Antonangeli F, Zingoni A, Soriani A, Santoni A. Senescent cells: Living or dying is a matter of NK cells. J Leukoc Biol. 2019;105(6):1275-83.","DOI":"10.1002\/JLB.MR0718-299R"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Prager I, Liesche C, van Ooijen H, Urlaub D, Verron Q, Sandstrom N, Fasbender F, Claus M, Eils R, Beaudouin J, Onfelt B, Watzl C. NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing. J Exp Med. 2019;216(9):2113-27.","DOI":"10.1084\/jem.20181454"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Chava S, Bugide S, Gupta R, Wajapeyee N. Measurement of natural killer cell-mediated cytotoxicity and migration in the context of hepatic tumor cells. J Vis Exp. 2020;156:10.3791\/60714.","DOI":"10.3791\/60714"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Kaur K, Nanut MP, Ko M-W, Safaie T, Kos J, Jewett A. Natural killer cells target and differentiate cancer stem-like cells\/undifferentiated tumors: Strategies to optimize their growth and expansion for effective cancer immunotherapy. Curr Opin Immunol. 2018;51:170-80.","DOI":"10.1016\/j.coi.2018.03.022"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Kaur K, Safaie T, Ko M-W, Wang Y, Jewett A. ADCC against MICA\/B is mediated against differentiated oral and pancreatic and not stem-like\/poorly differentiated tumors by the nk cells; loss in cancer patients due to down-modulation of CD16 receptor. Cancers. 2021;13(2):239.","DOI":"10.3390\/cancers13020239"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Buller CW, Mathew SO. NK cell isolation and cytotoxicity by radioactive chromium release assay and DELFIA-EuTDA cytotoxicity assay. Methods Mol Biol. 2022;2463:221-33.","DOI":"10.1007\/978-1-0716-2160-8_16"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Wong P, Wagner JA, Berrien-Elliott MM, Schappe T, Fehniger TA. Flow cytometry-based ex vivo murine NK cell cytotoxicity assay. STAR Protoc. 2021;2(1):100262.","DOI":"10.1016\/j.xpro.2020.100262"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Chan LL-Y, Wucherpfennig KW, de Andrade LF. Visualization and quantification of NK cell-mediated cytotoxicity over extended time periods by image cytometry. J Immunol Methods. 2019;469:47-51.","DOI":"10.1016\/j.jim.2019.04.001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"McLaren C, Bhise G, Job I, Otegbeye F. Comparison of different cytotoxicity assays and IFN-&#947; production for CAR-T cell products. Cytotherapy. 2025;27(5):S122.","DOI":"10.1016\/j.jcyt.2025.03.240"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Jurisic V, Vuletic A, Mirjacic-Martinovic K, Milovic-Kovacevic M, Radenkovic S, Knezevic S, Markovic O. Advantages and disadvantages of the assay for determining NK cell activity using radioactive chromium in clinical practice: Our experience. Euro Phys J Special Topics. 2025:1-8. doi: 10.1140\/epjs\/s11734-025-01694-w","DOI":"10.1140\/epjs\/s11734-025-01694-w"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Kaur K, Chen P-C, Jewett A. Supercharged NK cells: A unique population of NK cells capable of differentiating stem cells and lysis of MHC class I high differentiated tumors. Cell Death Disease. 2025;16(1):665.","DOI":"10.1038\/s41419-025-07986-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Huerta-Yepez S, Chen PC, Kaur K, Jain Y, Singh T, Esedebe F, Liao YJ, DiBernardo G, Moatamed NA, Mei A, Malarkannan S, Graeber TG, Memarzadeh S, Jewett A. Supercharged NK cells, unlike primary activated NK cells, effectively target ovarian cancer cells irrespective of MHC-class I expression. BMJ Oncol. 2025;4(1):e000618.","DOI":"10.1136\/bmjonc-2024-000618"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Sher E, Ko M-W, Kaur K, Jewett A. Processed osteoclasts similar to live osteoclasts are capable of supercharging natural killer (sNK) cells. Crit Rev Immunol. 2025;45(4):31-42.","DOI":"10.1615\/CritRevImmunol.2025056318"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Kaur K, Jewett A. Combination therapy of supercharged NK cells and ONC201 or ONC206 to target aggressive K27M brain tumor. Crit Rev Immunol. 2025;45(3):0.","DOI":"10.1615\/CritRevImmunol.2025058345"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Bui VT, Tseng HC, Kozlowska A, Maung PO, Kaur K, Topchyan P, Jewett A. Augmented IFN-&#947; and TNF-&#945; induced by probiotic bacteria in NK cells mediate differentiation of stem-like tumors leading to inhibition of tumor growth and reduction in inflammatory cytokine release; regulation by IL-10. Front Immunol. 2015;6:576.","DOI":"10.3389\/fimmu.2015.00576"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Kaur K, Kozlowska AK, Topchyan P, Ko MW, Ohanian N, Chiang J, Cook J, Maung PO, Park SH, Cacalano N, Fang C, Jewett A. Probiotic-treated super-charged NK cells efficiently clear poorly differentiated pancreatic tumors in Hu-BLT mice. Cancers. 2019;12(1):63.","DOI":"10.3390\/cancers12010063"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Kozlowska AK, Topchyan P, Kaur K, Tseng HC, Teruel A, Hiraga T, Jewett A. Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells\/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs. J Cancer. 2017;8(4):537-54.","DOI":"10.7150\/jca.15989"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Jewett A, Man Y-G, Tseng H-C. Dual functions of natural killer cells in selection and differentiation of stem cells; role in regulation of inflammation and regeneration of tissues. J Cancer. 2013;4(1):12-24.","DOI":"10.7150\/jca.5519"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Tseng HC, Bui V, Man YG, Cacalano N, Jewett A. Induction of split anergy conditions natural killer cells to promote differentiation of stem cells through cell-cell contact and secreted factors. Front Immunol. 2014;5:269.","DOI":"10.3389\/fimmu.2014.00269"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Jewett A, Bonavida B. Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol. 1996;156(3):907-15.","DOI":"10.4049\/jimmunol.156.3.907"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Tseng H-C, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, Alva JA, Walter G, Head C, Ishikawa TO, Herschman HR, Cacalano N, Pyle AD, Park NH, Jewett A. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One. 2010;5(7):e11590.","DOI":"10.1371\/journal.pone.0011590"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Kaur K, Chen P-C, Ko M-W, Mei A, Senjor E, Malarkannan S, Jewett A. Sequential therapy with supercharged NK cells with either chemotherapy drug cisplatin or anti-PD-1 antibody decreases the tumor size and significantly enhances the NK function in Hu-BLT mice. Front Immunol. 2023;14:1132807.","DOI":"10.3389\/fimmu.2023.1132807"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Kaur K, Cook J, Park S-H, Topchyan P, Kozlowska A, Ohanian N, Fang C, Nishimura I, Jewett A. Novel strategy to expand super-charged NK cells with significant potential to lyse and differentiate cancer stem cells: differences in NK expansion and function between healthy and cancer patients. Front Immunol. 2017;8:297.","DOI":"10.3389\/fimmu.2017.00297"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Kaur K, Topchyan P, Kozlowska AK, Ohanian N, Chiang J, Maung PO, Park SH, Ko MW, Fang C, Nishimura I, Jewett A. Super-charged NK cells inhibit growth and progression of stem-like\/poorly differentiated oral tumors in vivo in humanized BLT mice; effect on tumor differentiation and response to chemotherapeutic drugs. OncoImmunology. 2018;7(5):e1426518.","DOI":"10.1080\/2162402X.2018.1426518"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Chovatiya N, Kaur K, Huerta-Yepez S, Chen P-C, Neal A, DiBernardo G, Gumrukcu S, Memarzadeh S, Jewett A. Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity. Cancer Immunol Immunother. 2022;71(12):2929-41.","DOI":"10.1007\/s00262-022-03192-7"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Kaur K, Ko M-W, Ohanian N, Cook J, Jewett A. Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8&#43; T cells. Sci Rep. 2020;10(1):20363.","DOI":"10.1038\/s41598-020-76702-1"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Tseng HC, Inagaki A, Bui VT, Cacalano N, Kasahara N, Man YG, Jewett A. Differential targeting of stem cells and differentiated glioblastomas by NK cells. J Cancer. 2015;6(9):866-76.","DOI":"10.7150\/jca.11527"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Huerta-Yepez S, Gonzalez JD, Sheik N, Beraki S, Kathirvel E, Rodriguez-Frandsen A, Chen PC, Sargsyan T, Mahammad S, Dybul MR, Chen L, Binette F, Jewett A. Therapeutic efficacy of CD34-derived allogeneic dendritic cells engineered to express CD93, CD40L, and CXCL13 in humanized mouse models of pancreatic cancer. Vaccines. 2025;13(7):749.","DOI":"10.3390\/vaccines13070749"}],"container-title":["Critical Reviews in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/0a611626014032a0\/CRI-61706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:31:35Z","timestamp":1790793095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/2ff21abf44b19838,3cd8f7141fb7b275,0a611626014032a0.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevimmunol.2025061706","relation":{},"ISSN":["1040-8401"],"issn-type":[{"value":"1040-8401","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}